These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 22035455)

  • 1. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.
    Salomone S; Caraci F; Leggio GM; Fedotova J; Drago F
    Br J Clin Pharmacol; 2012 Apr; 73(4):504-17. PubMed ID: 22035455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
    Noetzli M; Eap CB
    Clin Pharmacokinet; 2013 Apr; 52(4):225-41. PubMed ID: 23408070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
    Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
    Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
    J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of therapies for Alzheimer's disease based on cholinergic hypothesis-status quo and future directions].
    Shimohama S
    Rinsho Shinkeigaku; 2013; 53(11):1036-8. PubMed ID: 24291871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current approaches to optimize treatment of dementia and Alzheimer's disease].
    Kolykhalov IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(6):87-92. PubMed ID: 28635795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
    J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Advances in Alzheimer's disease treatment].
    Nourhashémi F
    Rev Med Interne; 2006 Aug; 27(8):585-7. PubMed ID: 16782240
    [No Abstract]   [Full Text] [Related]  

  • 12. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
    Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
    Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges and Approaches of Drugs Such as Memantine, Donepezil, Rivastigmine, and Aducanumab in the Treatment, Control and Management of Alzheimer's Disease.
    Saeedi M; Mehranfar F
    Recent Pat Biotechnol; 2022; 16(2):102-121. PubMed ID: 35236274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Are anti-dementia drugs worthwhile?].
    Lang CJ
    MMW Fortschr Med; 2007 Sep; 149 Suppl 3():85-9. PubMed ID: 17955784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?
    Ehret MJ; Chamberlin KW
    Clin Ther; 2015 Aug; 37(8):1604-16. PubMed ID: 26122885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?
    Sevilla C; Jiménez Caballero PE; Alfonso V; González-Adalid M
    Dement Geriatr Cogn Disord; 2009; 28(3):196-205. PubMed ID: 19738386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug therapy of dementia in elderly patients. A review.
    Olsen CE; Poulsen HD; Lublin HK
    Nord J Psychiatry; 2005; 59(2):71-7. PubMed ID: 16195103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-Dementia Drugs (Anti-Alzheimer's Disease Drugs)].
    Yamada M
    Brain Nerve; 2023 May; 75(5):464-469. PubMed ID: 37194514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Alzheimer's disease: current status and new perspectives.
    Scarpini E; Scheltens P; Feldman H
    Lancet Neurol; 2003 Sep; 2(9):539-47. PubMed ID: 12941576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drugs for Alzheimer's disease in Japan.
    Takeda M; Tanaka T; Okochi M
    Psychiatry Clin Neurosci; 2011 Aug; 65(5):399-404. PubMed ID: 21851448
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 32.